11.18.16
Evonik is expanding its production facilities in Birmingham, AL and Darmstadt, Germany for additional capacity to produce biodegradable polymers marketed globally as RESOMER and RESOMER SELECT. These poly-lactic-glycolic-acid (PLGA) copolymers are primarily used to manufacture bioresorbable medical devices and controlled-release formulations for parenteral drug delivery.
“We expect the global demand for biodegradable polymers to continue to grow in the coming years,” said Paul Spencer, head of Biomaterials at Evonik’s Health Care Business Line. “With this in mind, we are currently investing to increase the capacity of our production facilities in order to serve our global customer base.”
The company will add new building adjacent to its existing facility in Birmingham, with greater production capacity, as well as clean rooms and a lab for polymer contract research projects. Commissioning is slated for late 2018.
The company will also be opening a new production line in Darmstadt, along with an applied technology lab to support medical device customers.
“We expect the global demand for biodegradable polymers to continue to grow in the coming years,” said Paul Spencer, head of Biomaterials at Evonik’s Health Care Business Line. “With this in mind, we are currently investing to increase the capacity of our production facilities in order to serve our global customer base.”
The company will add new building adjacent to its existing facility in Birmingham, with greater production capacity, as well as clean rooms and a lab for polymer contract research projects. Commissioning is slated for late 2018.
The company will also be opening a new production line in Darmstadt, along with an applied technology lab to support medical device customers.